It's in the Genes: How Genetics Is Reshaping Our Understanding of PAH

Many health awareness campaigns around the world attribute the progression of diseases to environmental and lifestyle factors; however, genetics is often forgotten. For many diseases, a patient’s genetics is an important biological driver. Genetics is a branch of biology focusing on genes, heredity and genetic variation. All of these combine to explain how traits and diseases can be passed from parents to their children through DNA.

In a consensus report summarizing the 7th World Symposium on Pulmonary Hypertension, experts identified 12 genes associated with heritable pulmonary arterial hypertension (PAH) so far, such as BMPR2, TBX4 and SOX17. These genes do not all contribute to PAH in the same way. BMPR2 mutations are behind most PAH cases we currently identify as heritable and result in unregulated growth and function of cells lining pulmonary blood vessels. TBX4 and SOX17 mutations are rarer, but no less important, as TBX4 helps shape the lungs during development and SOX17 keeps blood vessel walls intact and functioning. Although each gene affects a different pathway, the result is the same: blood vessels thicken and narrow, forcing the heart to work harder to pump blood to the lungs.

Beyond understanding the biology of the disease, the paper also sets clear guidelines on genetic testing in both patients and family members, even in those without symptoms. It also explores more personalized approaches, such as gene editing and targeted mRNA therapies, that may one day take us to personalized care, though these remain largely experimental today.

Genetics is therefore no longer something that belongs only in the laboratory. Today, genetic knowledge is already helping physicians better understand, manage and treat pulmonary hypertension. Ultimately, mapping the genome isn't just about understanding why PAH happens; it's about changing what happens next. As targeted genetic therapies continue moving from bench toward bedside, knowing a patient's exact DNA profile is already reshaping diagnosis and family risk assessment, holding real promise for more targeted treatment in the years ahead.